Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN)

• Published in: Journal of clinical oncology Vol. 40; no. 16_suppl; p. e21140
• Main Authors: Han, Baohui, Yan, Bo, Gu, Aiqin, Chu, Tianqing, Zhang, Wei, Wang, Huiming, Zhong, Hua, Shi, Chunlei, Zhang, Xueyan
• Format: Journal Article
• Language: English
• Published: 01.06.2022

e21140 Background: Limited data is known regarding osimertinib plus anlotinib as first line treatment in EGFRm advanced NSCLC patients. Earlier we have reported that osimertinib in combination with anlotinib was well tolerated. Here we further present the efficacy and safety profile of the combined...